OptimizeRx Lowers FY2026 Sales Guidance from $118.000M-$124.000M to $109.000M-$114.000M
Benzinga Newsdesk 8 months ago
NewsGuidance
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.